Citizens JMP raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $135 from $130 and keeps an Outperform rating on the shares. Sales of imcivree remain strong with setmelanotide approval in HO likely next year and multiple readouts in the near-term, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals Reports Strong Q2 2025 Growth
- Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley
- Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating
- Rhythm Pharmaceuticals reports Q2 EPS (75c), consensus (67c)
- Rhythm Pharmaceuticals announces anticipated upcoming milestones